[
  {
    "ts": null,
    "headline": "Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential",
    "summary": "Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential",
    "url": "https://finnhub.io/api/news?id=23b060bab3e63c2acac03f90f8176364f2746e75380bbd95fee77f0345e8f839",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744909654,
      "headline": "Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential",
      "id": 133960246,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=23b060bab3e63c2acac03f90f8176364f2746e75380bbd95fee77f0345e8f839"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?",
    "summary": "Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.",
    "url": "https://finnhub.io/api/news?id=c59d858f95b4e6bb6a99c5a62f9f524ed424c13d03e5a147104fd186eebeaaeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744909560,
      "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?",
      "id": 133964653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.",
      "url": "https://finnhub.io/api/news?id=c59d858f95b4e6bb6a99c5a62f9f524ed424c13d03e5a147104fd186eebeaaeb"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=e4eac7011021c813c1ae4a6aac93cbc134d05ba88a928988110f67b37921710a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744898470,
      "headline": "Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 133958621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=e4eac7011021c813c1ae4a6aac93cbc134d05ba88a928988110f67b37921710a"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys",
    "summary": "My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys",
    "url": "https://finnhub.io/api/news?id=3583de69a5b9294d49cfc850c02d9e183a0af145eb6a1cde6d77ee1e1a833ab0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744877400,
      "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys",
      "id": 133942183,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3583de69a5b9294d49cfc850c02d9e183a0af145eb6a1cde6d77ee1e1a833ab0"
    }
  }
]